OLMA
Olema Pharmaceuticals, Inc.
There isn't enough reported data to score OLMA yet.
OLMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
OLMA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
OLMA PE Valuation
OLMA has no meaningful PE right now: it lost money over the past year.
OLMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OLMA's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OLMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.37 | -$0.51 |
| Q2 2026 | -$2.13 | -$0.16 |
| Q1 2026 | -$2.03 | -$0.03 |
| Q4 2025 | -$1.87 | +$0.33 |
| Q3 2025 | -$1.86 | +$0.32 |
| Q2 2025 | -$1.97 | +$0.09 |
| Q1 2025 | -$2.00 | +$0.01 |
| Q4 2024 | -$2.20 | -$0.06 |
OLMA lost $2.37 per share over the past year, a bigger loss than the year before.
OLMA Quarterly Revenue
OLMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$48M | -$13.5M |
| Q3 2025 | -$34.5M | -$7.5M |
| Q4 2022 | -$19.9M | -$582K |
| Q3 2022 | -$18.1M | -$5.9M |
| Q2 2022 | -$26.5M | -$17.2M |
| Q1 2022 | -$17.9M | -$6.4M |
| Q4 2021 | -$19.3M | -$10.2M |
| Q3 2021 | -$12.2M | -$4.7M |
OLMA has burned cash in almost every quarter: −$155M over the past year, against −$98M the year before.
OLMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -3.4M shares |
| 1 year | +18% | +15.4M shares |
| 3 years | +125% | +56.1M shares |
| 5 years | +155% | +61.5M shares |
| Available history | +617% | +87M shares |
OLMA has 101M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | $2.3M |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OLMA Net Leverage
OLMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OLMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 17.3 | Oversold |
OLMA's weekly RSI is 36 (neutral) and its Stochastic is 17 (oversold).
OLMA PE vs Healthcare Sector
OLMA has no meaningful PE right now: it lost money over the past year.
OLMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.46 | 0.8% above |
| 20 week MA | $9.66 | 22% below |
| 50 week MA | $15.5 | 51% below |
| 100 week MA | $11.1 | 32% below |
| 200 week MA | $10.6 | 29% below |
OLMA has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 29% below its 200-week average.
OLMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.9 | $51.5 | +5.3% |
| 2021 | $51.5 | $9.91 | -81% |
| 2022 | $9.91 | $2.65 | -73% |
| 2023 | $2.65 | $14.0 | +429% |
| 2024 | $14.0 | $6.15 | -56% |
| 2025 | $6.15 | $26.2 | +327% |
| 2026 YTD | $26.2 | $7.52 | -71% |
OLMA's yearly returns have swung widely, from +429% in 2023 to −81% in 2021. It's down 71% so far in 2026.